Standard treatment with bevacizumab as targeted therapy in cervical cancer
Rev. invest. clín
;
72(4): 213-218, Jul.-Aug. 2020.
Artículo
en Inglés
| LILACS
| ID: biblio-1251858
ABSTRACT
ABSTRACT Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Neoplasias del Cuello Uterino
/
Bevacizumab
Tipo de estudio:
Estudio pronóstico
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Rev. invest. clín
Asunto de la revista:
Medicina
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Dinamarca
/
India
/
México
Institución/País de afiliación:
Centro Médico Nacional 20 de Noviembre/MX
/
Instituto Nacional de Cancerología/MX
/
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado/MX
Similares
MEDLINE
...
LILACS
LIS